Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | CRHBP | P24387 | 1/20 | 0.42 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3064745 | 0.88 | TGFBR1 (0.38) | GRM2MAPTKDM4ELMNA | |
| SCHEMBL3059995 | 0.84 | KMT2A (0.42) | MAPTGAAALDH1A1MEN1KMT2A | |
| SCHEMBL3065381 | 0.82 | TP53 (0.43) | MAPTGAAPDE10A | |
| SCHEMBL3059646 | 0.81 | RPS6KA5 (0.37) | GRM2MAPTNPC1RAB9ACASP1 | |
| SCHEMBL3055685 | 0.80 | MAPT (0.49) | GRM2MAPTGAAPKMSMN1; SMN2 | |
| SCHEMBL13089471 | 0.80 | GRM2 (0.35) | GRM2 | |
| SCHEMBL3055145 | 0.78 | TGFBR1 (0.36) | MAPTLMNA | |
| SCHEMBL3061531 | 0.78 | S1PR1 (0.42) | CYP3A4CYP2C19PDE10A | |
| SCHEMBL3060438 | 0.78 | CNR2 (0.40) | GAAALDH1A1MEN1KMT2ANPC1 | |
| SCHEMBL3055208 | 0.78 | MAPT (0.48) | GRM2MAPTGAAPKMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7642267-B2 | Benzimidazole and pyridylimidazole derivatives | NEUROGEN CORPORATION (US) | 2010-01-05 | — | — | US | disclosed |
| US-20080227793-A1 | Benzimidazole and Pyridylimidazole Derivatives | NEUROGEN CORPORATION | 2008-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227793-A1 | Benzimidazole and Pyridylimidazole Derivatives | GABBR1, GABBR2, GABRA2 | GRM2 217/4885MAPT 1046/4885GAA 1402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.